Global Accelerator for Paediatric Formulations (GAP-f): Presentation at the 9th Annual Conference of the European Paediatric Formulation Initiative (EuPFI)
20 September 2017 | Warsaw, Poland
Limited treatment options and sub-optimal formulations have contributed to poor adherence and outcomes for children living with HIV. Despite the need for expanded and improved options for paediatric treatment, barriers to incentivizing research and development remain. The GAP-f aims to promote a faster, more efficient and more focused approach to paediatric formulation development. It is a collaborative framework that can help get better paediatric products quicker and cheaper by prioritizing products, streamlining the generation of clinical evidence, incentivizing manufacturers, accelerating product development and introduction, and coordinating procurement. The ILF brings the industry perspective to the GAP-f development, in collaboration with other GAP-f partners (WHO, MPP, DNDi, CHAI, Unitaid, Global Fund, PEPFAR and CIPHER).
The GAP-f concepts, goals and proposed timeline of activities were recently presented at the 9th Annual Conference of the European Paediatric Formulation Initiative (EuPFI).